Dupont Jakob
Known title: EVP, Head of R&DCIK: 0001553335
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Transaction History
| PYXS | ▲ Buy | Option Exercise | 35,000 | $56K | 6/30/2026 | View on chart |
| PYXS | ▼ Sell | Open Market | 35,000 | $107K | 6/30/2026 | View on chart |
| PYXS | ▲ Buy | Grant | 38,741 | $0 | 3/26/2024 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,074 | $18K | 3/2/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 141,328 | $0 | 3/1/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,124 | $5K | 11/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 3,218 | $14K | 11/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 4,124 | $21K | 8/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 3,873 | $21K | 5/17/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 2,221 | $22K | 3/1/2022 | View on chart |
| ATRA | ▲ Buy | Grant | 78,506 | $0 | 3/1/2022 | View on chart |
| ATRA | ▲ Buy | Option Exercise | 5,000 | $48K | 2/10/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,000 | $80K | 2/10/2022 | View on chart |
| ATRA | ▲ Buy | Option Exercise | 5,000 | $48K | 1/3/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,000 | $80K | 1/3/2022 | View on chart |
| ATRA | ▲ Buy | Option Exercise | 5,000 | $48K | 12/1/2021 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,000 | $90K | 12/1/2021 | View on chart |
| ATRA | ▼ Sell | Open Market | 2,199 | $38K | 11/16/2021 | View on chart |
| ATRA | ▲ Buy | Option Exercise | 5,000 | $48K | 11/2/2021 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,000 | $82K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.